ArticleThe EPMA journal2020
Effect of probiotics on obesity-related markers per enterotype: a double-blind, placebo-controlled, randomized clinical trial.
Article in The EPMA journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Efficacy of probiotic supplementation for body weight management in overweight and obese adults: a meta-analysis of randomized controlled trials predominantly from East Asia.Frontiers in public health · 2026Pooled it
- Probiotics' effect on visceral and subcutaneous adipose tissue: a systematic review of randomized controlled trials.European journal of clinical nutrition · 2022Pooled it
- Effects of Probiotics and Synbiotics on Weight Loss in Subjects with Overweight or Obesity: A Systematic Review.Nutrients · 2021Pooled it
- Effect of synbiotic supplementation on immune parameters and gut microbiota in healthy adults: a double-blind randomized controlled trial.Gut microbes · 2023Trial
- Gut Microbiota Serves a Predictable Outcome of Short-Term Low-Carbohydrate Diet (LCD) Intervention for Patients with Obesity.Microbiology spectrum · 2021Trial
- Trial
- Probiotics in Cardiometabolic Diseases: Current Evidence, Postbiotic Perspectives, and Future Directions.Journal of microbiology and biotechnology · 2026Review
- Probiotic Modulation of Gut Microbiota: Antioxidant Mechanisms and Clinical Benefits in Obesity and Type 2 Diabetes Management.Antioxidants (Basel, Switzerland) · 2026Review
- Postbiotics: Novel Modulators of Gut Health, Metabolism, and Their Mechanisms of Action.Probiotics and antimicrobial proteins · 2026Review
- The novel synbiotic (Lactiplantibacillus plantarum and galacto-oligosaccharides) ameliorates obesity-related metabolic dysfunction: Arginine as a key mediator signaling molecule.Journal of advanced research · 2026Article
- Review
- Multimodal (Bio)Markers and Risk of Obesity - A Comprehensive Scoping Review.Advances in nutrition (Bethesda, Md.) · 2026Article
- Gut Microbial Composition, Oxidative Stress, and Immunity in Metabolic Disease: Toward Personalized Interventions.Antioxidants (Basel, Switzerland) · 2026Review
- Article
- Microbiota management: a perspective for kidney transplant patients.Frontiers in transplantation · 2026Review
- Harnessing Probiotics: Exploring the Role of the Gut Microbiome in Combating Obesity.Probiotics and antimicrobial proteins · 2025Review
- Article
- Causal Relationships Between Iron Deficiency Anemia, Gut Microbiota, and Metabolites: Insights from Mendelian Randomization and In Vivo Data.Biomedicines · 2025Article
- An update and overview of the various health-related benefits of probiotics: A focus on clinical trials demonstrating efficacy, tolerability and use in patients with impaired glucose tolerance and type 2 diabetes.Diabetes, obesity & metabolism · 2025Review
- Double Emulsion Microencapsulation System forFoods (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevention and improvement of disease symptoms are important issues, and probiotics are suggested as a good treatment for controlling the obesity. Human gut microbiota has different community structures. Because gut microbial composition is assumed to be linked to probiotic function, this study evaluated the efficacy of probiotics on obesity-related clinical markers according to gut microbial enterotype.
methodsFifty subjects with body mass index over 25 kg/m
resultsGut microbial compositions of all the subjects were classified into two enterotypes according to
conclusionAdministration of probiotics improved obesity-related markers in obese people, and the efficacy of probiotics differed per gut microbial enterotype and greater responses were observed in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.